What is the appropriate post‑exposure prophylaxis for a healthcare worker after a needle‑stick injury, including HIV, hepatitis B, hepatitis C, and tetanus considerations?

Post-Exposure Prophylaxis for Needle Stick Injuries

Immediately wash the wound with soap and water, flush mucous membranes with water, then rapidly assess the source patient's HBV, HCV, and HIV status to determine appropriate prophylaxis—with HIV PEP needing initiation within 72 hours (ideally within 2 hours) for maximum effectiveness. 1

Immediate Wound Care

• Wash wounds and skin with soap and water 1
• Flush mucous membranes with water 1
• Do NOT squeeze or manipulate the wound excessively 1

Risk Assessment Framework

Evaluate the Exposure Type

• Percutaneous injury (needle stick, cut with sharp object) poses highest risk 1
• Mucous membrane exposure (splash to eyes, nose, mouth) poses moderate risk 1
• Non-intact skin exposure poses lower risk 1
• Consider the volume of blood and depth of injury when stratifying risk 1

Evaluate the Source Patient

• Test source immediately for HBsAg, anti-HCV, and HIV antibody using rapid testing if available 1
• If source is unknown, assess epidemiologic risk factors for bloodborne pathogens 1
• Do NOT test discarded needles or syringes for virus contamination 1

Evaluate the Exposed Healthcare Worker

• Determine hepatitis B vaccination history and vaccine response status 1
• Obtain baseline HIV and HCV testing 1
• Document tetanus immunization status 1

Hepatitis B Post-Exposure Prophylaxis

For Unvaccinated or Incompletely Vaccinated HCW:

• Initiate hepatitis B vaccine series immediately 1
• Add HBIG (Hepatitis B Immune Globulin) if source is HBsAg-positive or high-risk 1, 2
• HBIG should be given within 24 hours (up to 7 days acceptable) 2

For Vaccinated HCW with Known Response:

• No treatment needed if anti-HBs ≥10 mIU/mL 1
• If anti-HBs <10 mIU/mL and source is HBsAg-positive: give HBIG plus vaccine booster 1

For Vaccinated HCW with Unknown Response:

• Test anti-HBs level immediately 1
• If source is HBsAg-positive and anti-HBs result pending: give HBIG and vaccine booster 1

Follow-up Testing:

• Test for anti-HBs 1-2 months after last vaccine dose 1
• Anti-HBs response cannot be accurately assessed if HBIG was given in the previous 3-4 months 1

Hepatitis C Post-Exposure Management

No post-exposure prophylaxis is recommended for HCV—only surveillance is indicated. 1

Baseline and Follow-up Testing:

• Obtain baseline anti-HCV and ALT immediately 1
• Repeat anti-HCV and ALT at 4-6 months post-exposure 1
• Consider HCV RNA testing at 4-6 weeks if earlier diagnosis is desired 1
• Confirm repeatedly reactive anti-HCV EIA results with supplemental testing 1

Critical Pitfall:

• Immune globulin and antiviral agents (interferon with or without ribavirin) should NOT be used for HCV PEP 2

HIV Post-Exposure Prophylaxis

HIV PEP must be initiated as soon as possible—ideally within 2 hours and no later than 72 hours after exposure—for maximum effectiveness. 1

Indications for HIV PEP:

• High-risk percutaneous injury from HIV-positive source 1
• Large-volume blood exposure from HIV-positive source 1
• Source with unknown HIV status but high epidemiologic risk (consider case-by-case) 1

Basic HIV PEP Regimen (2001 Guidelines):

• Zidovudine (ZDV/AZT) 600 mg daily in 2-3 divided doses PLUS Lamivudine (3TC) 150 mg twice daily 1
• Available as combination tablet (Combivir) for twice-daily dosing 1
• Duration: 4 weeks (28 days) 1

Alternative Basic Regimens:

• Lamivudine (3TC) 150 mg twice daily PLUS Stavudine (d4T) 40 mg twice daily (30 mg if <60 kg) 1
• Didanosine (ddI) plus Stavudine (d4T) 1

Expanded Regimen Considerations:

• Add a third drug for high-risk exposures (large-volume blood, deep injury, visible blood on device, source with high viral load) 1, 2
• Consult infectious disease specialist or PEPline (888-448-4911) for complex cases 1

Drugs to AVOID:

• Nevirapine should NOT be used due to severe hepatic and cutaneous toxicity risk 1
• Efavirenz should NOT be used if pregnancy is known or suspected due to teratogenicity 1

Baseline Testing Before PEP:

• HIV rapid test (blood or oral fluid) 1
• Complete blood count, renal function, hepatic function tests 1
• Pregnancy test in women (must have result before considering efavirenz) 1

Follow-up During PEP:

• Reassess within 72 hours for adherence, toxicity, and baseline test results 1
• Monitor CBC, renal and hepatic function at 2 weeks 1
• Provide 5-7 day starter pack for ambulatory patients 1
• 88.6% of patients experience drug-related adverse events—provide antimotility and antiemetic agents proactively 3

HIV Serologic Follow-up (Modern 2025 Approach):

• Perform both laboratory Ag/Ab test AND diagnostic NAT at follow-up visits to improve detection sensitivity when antiretroviral prophylaxis may suppress viral load 4
• First follow-up at 4-6 weeks after PEP initiation (approximately 2 weeks after completing 28-day course) 4
• Final follow-up at 12 weeks after PEP initiation (about 8 weeks after PEP completion) to definitively rule out HIV infection 4
• Traditional schedule: baseline, 6 weeks, 3 months, and 6 months 1
• Extend follow-up to 12 months if HCV co-infection occurs 4

Critical Pitfalls:

• A negative HIV test 4-6 weeks after PEP initiation does NOT exclude infection because antiretrovirals may suppress detectable virus for longer than 2 weeks after stopping therapy 4
• Oral-fluid rapid HIV tests are NOT recommended for PEP follow-up due to lower sensitivity for acute infection 4
• Test immediately if acute retroviral syndrome symptoms develop at any point during follow-up 1, 4
• Counsel on precautions to prevent secondary transmission throughout the entire follow-up period 1, 4

Tetanus Prophylaxis

• Assess tetanus immunization status 1
• Administer tetanus toxoid if last dose >5 years ago for contaminated wounds 1
• Administer tetanus toxoid if last dose >10 years ago for clean wounds 1
• Use separate syringes and anatomic sites when giving tetanus toxoid and TIG concurrently 1
• Hepatitis B vaccine and tetanus toxoid may be given simultaneously using separate sites 1

Timing Imperatives

Time is critical—delays reduce prophylaxis effectiveness:

• HIV PEP: Start within 2 hours (maximum 72 hours) 1
• HBIG: Give within 24 hours (up to 7 days acceptable) 2
• Hepatitis B vaccine: Start immediately 1
• Do NOT delay PEP while awaiting source patient test results 1

Common Pitfalls to Avoid

• Never test discarded needles—always attempt to identify and test the source patient 1
• Do not withhold HIV PEP pending baseline test results—initiate immediately if indicated 1
• Do not use HCV antivirals or immune globulin for HCV PEP—they are ineffective 1, 2
• Ensure adherence counseling—completion rates for HIV PEP are only 73.1% due to side effects 3
• Monitor for acute retroviral syndrome symptoms throughout follow-up—test immediately if they occur 1, 4
• Remember that PEP can delay seroconversion detection—use combined Ag/Ab plus NAT testing at follow-up 4